20 December 2021 - FDA has approved Xarelto (rivaroxaban) as tablets and an oral suspension to treat venous thromboembolism, or blood clots that form in the veins, and reduce the risk of venous thromboembolism recurring in paediatric patients from birth to younger than 18 years who have received at least five days of injectable or intravenous treatment for blood clots.

Today, FDA has also approved Xarelto to prevent blood clots in paediatric patients two years and older with congenital (present from birth) heart disease after the Fontan procedure, a type of open-heart surgery.

Read FDA press release